Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups
- Sprache
-
Englisch
- Identifier
-
1301845752
- Beteiligte Personen und Organisationen
-
Höh, Robert Benedikt
Würnschimmel, Christoph
Flammia, Rocco Simone
Horlemann, Benedikt
Sorce, Gabriele
Chierigo, Francesco
Tian, Zhe
Saad, Fred
Graefen, Markus
Gallucci, Michele
Briganti, Alberto
Terrone, Carlo
Shariat, Shahrokh F.
Tilki, Derya
Kluth, Luis
Mandel, Philipp
Chun, Felix
Karakiewicz, Pierre I.
- DOI
-
10.1002/pros.24312
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.10.2023, 11:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Höh, Robert Benedikt
- Würnschimmel, Christoph
- Flammia, Rocco Simone
- Horlemann, Benedikt
- Sorce, Gabriele
- Chierigo, Francesco
- Tian, Zhe
- Saad, Fred
- Graefen, Markus
- Gallucci, Michele
- Briganti, Alberto
- Terrone, Carlo
- Shariat, Shahrokh F.
- Tilki, Derya
- Kluth, Luis
- Mandel, Philipp
- Chun, Felix
- Karakiewicz, Pierre I.
Ähnliche Objekte (12)
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Diabetes and beta adrenergic blockage are risk factors for metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug
Mechanism of cancer evading metronomic chemotherapy and action of archazolid as an anti-metastatic drug
Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Angiogenesis as therapeutic target in metastatic prostate cancer – narrowing the gap between bench and bedside
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Diabetes and beta adrenergic blockage are risk factors for metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug
Mechanism of cancer evading metronomic chemotherapy and action of archazolid as an anti-metastatic drug
Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer
Angiogenesis as therapeutic target in metastatic prostate cancer – narrowing the gap between bench and bedside
Fractionated follow-up chemotherapy delays the onset of resistance in bone metastatic prostate cancer
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
Diabetes and beta adrenergic blockage are risk factors for metastatic prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth In Vivo
Mechanism of cancer evading metronomic chemotherapy and action of Archazolid as an anti-metastatic drug
Mechanism of cancer evading metronomic chemotherapy and action of archazolid as an anti-metastatic drug
Evolution of RAS mutational status in liquid biopsies during first-line chemotherapy for metastatic colorectal cancer
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer